近日，远大医药(0512.HK)冠脉血管内冲击波系统获NMPA批准上市。这是公司在心脑血管精准介入诊疗领域冠脉介入方向的又一步坚实的进展。在冠心病介入治疗中，钙化病变一直是困扰心血管医生的“硬骨头”。球囊难以充分扩张，许多技术又面临操作复杂、并发症风险高等挑战。而冠脉冲击波球囊的出现，以其独特的“声波爆破”技术，为复杂钙化病变提供了新的解决方案。冲击波球囊将泌尿外科的碎石原理创新应用于血管内，通过...
Source Link近日，远大医药(0512.HK)冠脉血管内冲击波系统获NMPA批准上市。这是公司在心脑血管精准介入诊疗领域冠脉介入方向的又一步坚实的进展。在冠心病介入治疗中，钙化病变一直是困扰心血管医生的“硬骨头”。球囊难以充分扩张，许多技术又面临操作复杂、并发症风险高等挑战。而冠脉冲击波球囊的出现，以其独特的“声波爆破”技术，为复杂钙化病变提供了新的解决方案。冲击波球囊将泌尿外科的碎石原理创新应用于血管内，通过...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.